NL-OMON42319已完成不适用
A double-blind, placebo controlled, randomised, parallel group study with an open-label cross-over part, investigating safety, tolerability, pharmacokinetics, and pharmacodynamics after single ascending oral doses and a single intravenous dose of the vasopressin V2-receptor agonist FE 202217 - FE 202217 SAD and cross-over study
PRA Health Sciences0 个研究点目标入组 52 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- healthy male or female
- •- 18-45 years old inclusive
- •- BMI between 18.5 - 29.9 kg/m2
- •- non smoker
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90
- •days before the start of this study or being a blood donor within 60 days from the start of the study. In case of
- •donating more than 1.5 liters of blood in the 10 months prior the start of this study
研究者
相似试验
进行中（未招募）
不适用
A double-blind, placebo controlled, randomised, parallel group phase IIa study to investigate the efficacy, tolerability, and safety of different dosing regimens of AZD8848 administered intranasally to seasonal allergic rhinitis patients out of pollen season in a nasal allergen challenge modelMedDRA version: 12.1Level: LLTClassification code 10001723Term: Allergic rhinitisAllergic RhinitisEUCTR2010-020747-13-SEAstraZeneca AB
进行中（未招募）
1 期
A double-blind, placebo controlled, randomised, parallel group, single centre, phase IIa study to investigate the efficacy, tolerability and safety of 8 doses of AZD8848 administered intranasally once weekly in mild to moderate allergic asthma patients challenged with an inhaled allergen.MedDRA version: 12.0 Level: LLT Classification code 10001705 Term: Allergic asthmaAllergic AsthmaEUCTR2009-013705-34-GBAstraZeneca AB
已完成
不适用
A double-blind, placebo controlled, randomised, parallel group study with an open-label cross-over part, investigating safety, tolerability, pharmacokinetics, and pharmacodynamics after single ascending oral doses and a single intravenous dose of the vasopressin V2-receptor agonist FE 201836octurianight voidingNL-OMON43629Ferring76
已完成
不适用
A clinical study to evaluate the efficacy and safety of Libidolyn�® when compared with placebo in improving sexual health of male subjects.CTRI/2022/03/041069Herbalyn Lifesciences Inc60
已完成
不适用
This is a study to evaluate the efficacy and safety of Slimilyn�® Capsules verses placebo in overweight and obese adult subjects.CTRI/2022/03/040987Herbalyn Lifesciences Inc60